Transaction · 0001577014-26-000016

Rhodes Jason P

Rhodes Jason P, DIR, reported an open-market or private sale at Dyne Therapeutics, Inc. involving 63643.000000 shares for an estimated $1667446.60. Reported holdings after the transaction were 751411.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SDIR
DYNDyne Therapeutics, Inc.
Trade date
Aug 13, 2026
Filing date
Aug 17, 2026
View on SEC Insider profile
Estimated value-$1.66MShares × reported price
Shares traded63.6k$26.20 per share
Holdings after751kIndirect · See footnote
% of reported position traded7.81%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 815,054 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

DYN price since this filing

Daily closing prices, with the filing date and available return windows
DYN · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -9.1%1w ago -1.0%1d ago +0.1%
Returns since7d -0.6%30d -33.8%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001577014-26-000016
Common Stock
Transaction date
Aug 13, 2026
Filed Aug 17, 2026, 09:30 PM · 4d delay
Shares
63,643 sh
$26.20 per share
Estimated value
-$1.66M
Computed from shares × price
Holdings after
751,411 sh
Indirect · See footnote

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Large Sale Repeat Seller 10b5-1 Detected
Filing-only score

-10 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026.

  2. F2

    The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to…

  3. F3

    The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture As…

  4. F4

    The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associ…

  5. F5

    The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates…

  6. F6

    The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive.

  7. F7

    The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securitie…

Original filing · 0001577014-26-000016
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

DYN